**PHS OTHER SUPPORT**

**For All Application Types – DO NOT SUBMIT UNLESS REQUESTED**

*There is no "form page" for reporting Other Support. Information on Other Support should be provided in the format shown below.*

\*Name of Individual: Mauro Martins Teixeira

Commons ID: MTEIXEIRA\_UFMG

**Other Support – Project/Proposal**

\*Title: A cluster-randomized trial to Evaluate the efficacy of Wolbachia-Infected Aedes aegypti mosquitoes in reducing the incidence of ***Arboviral infection*** in Brazil (Evita Dengue).

\*Major Goals: Clinical trial to evaluate the efficacy of mosquito-based strategy to reduce incidence of arboviral infection. This is a school-based, cluster trial carried out in the city of Belo Horizonte with 58 clusters and 60 children in each cluster.

\*Status of Support: **Active**

Project Number: **Emory VTEU** DMID Protocol Number: 17-0111

Name of PD/PI: Mauro Teixeira (Brazil)/Sri Edupuganthi (Emory)/Albert Ko (Yale)/ Derek Cummings (Florida)

\*Source of Support: **NIAID/**

\*Primary Place of Performance: Belo Horizonte, Brazil

Project/Proposal Start and End Date: (MM/YYYY) (if available): 03/2020 to 12/2024

\* Total Award Amount (including Indirect Costs): US$8,000,000.00

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2020 | 1.8 |
| 2. 2021  | 1.8 |
| 3. 2022 | 1.8 |
| 4. 2023 | 1.8 |
| 5. 2024 | 1.2 |

\*Title: Finding treatments for COVID-19: A phase 2 multi-centre adaptive platform trial to assess antiviral pharmacodynamics in early symptomatic COVID-19 (PLATCOV)

\*Major Goals: An adaptive trial designed to develop a platform to test anti-viral activity of existing and novel compounds in patients with COVID-19. The anti-viral activity is evaluated as the rate of decline of viral loads from inclusion to day 7.

\*Status of Support: **Active**

Name of PD/PI: PI: Nick White; Brazilian PI: Mauro Teixeira

\*Source of Support: Wellcome Trust

\*Primary Place of Performance: MORU Tropical Health, Bangkok, Thailand and Belo Horizonte, Brazil

Project/Proposal Start and End Date: 07/2021-06/2024

\* Total Award Amount (including Indirect Costs): BRL $ 4,773,674.00 (1USD = 5.3 BRL)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2021 | 0.2 |
| 2. 2022  | 0.2 |
| 3. 2023 | 0.2 |
| 4. 2024 | 0.2 |

\*Title: National Institute for Science and Technology (INCT) for Dengue and host-microbial interactions.

\*Major Goals: This is a major national program grant focused on generating science to deal with dengue and the new arboviral infections (Zika and Chikungunya). The major goals of our institute are: i. Become a recognized center for dengue research and research related to host and microbial interactions; ii Become a recognized center for the training of students and personnel in the area of scientific research of the Institute.

Project Number:

\*Status of Support: **Active**

Name of PD/PI: PI: Mauro Teixeira

\*Source of Support: Brazilian Ministry of Science, Technology and Innovation via its finance agency (CNPq) and FAPEMIG

\*Primary Place of Performance: Belo Horizonte, Brazil

Project/Proposal Start and End Date: 01/01/2017-12/31/2024

\* Total Award Amount (including Indirect Costs): BRL $ 10,000,000.00 (1USD = 5.3 BRL)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2017-2020 | 1.0 |
| 2. 2021  | 1.0 |
| 3. 2022 | 1.0 |
| 4. 2023  | 1.0 |
| 5. 2024 | 1.0 |

\*Title: Research Network on Immunobiologicals and biodrugs for innovative and advanced therapies.

\*Major Goals: To develop lipid nanoparticle-based formulations to deliver pro-resolving and anti-viral proteins to treat infectious diseases

Project Number: RED-00202-22

\*Status of Support: **Active**

Name of PD/PI: PI: Mauro Teixeira

\*Source of Support: FAPEMIG, Minas Gerais, Brazil

\*Primary Place of Performance: Belo Horizonte, Brazil

Project/Proposal Start and End Date: 07/2022 – 07/2024

\* Total Award Amount (including Indirect Costs): BRL $ 1,500,000.00 (1USD = 5.3 BRL)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.2 |
| 2. 2023  | 0.2 |
| 3. 2024 | 0.2 |

\*Title: Nucleic acid vaccines for neglected, tropical vector-transmitted diseases.

\*Major Goals: To Develop RNA-based lipid nanoparticle vaccine candidates against arboviral infections of interest, especially Chikungunya

Project Number: : 0439/22

\*Status of Support: **Active**

Name of PD/PI: PI: Mauro Teixeira

\*Source of Support: FAPEMIG, Minas Gerais, Brazil

\*Primary Place of Performance: Belo Horizonte, Brazil

Project/Proposal Start and End Date: 08/2022 – 08/2024

\* Total Award Amount (including Indirect Costs): BRL$ 2.728.530,00 (1USD = 5.3 BRL)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.3 |
| 2. 2023  | 0.3 |
| 3. 2024 | 0.3 |

\*Title: Nucleic acid vaccines for neglected, tropical vector-transmitted diseases.

\*Major Goals: To Develop RNA-based lipid nanoparticle vaccine candidates against arboviral infections of interest, especially Chikungunya

Project Number: : 0439/22

\*Status of Support: **Active**

Name of PD/PI: PI: Mauro Teixeira

\*Source of Support: FAPEMIG, Minas Gerais, Brazil

\*Primary Place of Performance: Belo Horizonte, Brazil

Project/Proposal Start and End Date: 08/2022 – 08/2024

\* Total Award Amount (including Indirect Costs): BRL$ 2.728.530,00 (1USD = 5.3 BRL)

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2022 | 0.3 |
| 2. 2023  | 0.3 |
| 3. 2024 | 0.3 |

\*Title: Phase III Clinical study to evaluate the efficacy of an attenuated Dengue I, 2, 3 and 4 vaccine developed by Butantan.

\*Major Goals: WE are one of the Clinical research sites responsible for testing a Dengue Vaccine Clinical Candidate developed by NIH and formulated by Butantan (enrolment of 1,079 individuals – recruitment ended Feburary 2019)

\*Status of Support: **Active**

Name of PD/PI: Site PI: Mauro Teixeira

\*Source of Support: Butatan Institute and Butantan Foundation

\*Primary Place of Performance: Belo Horizonte, Brazil and 15 other sites in Brazil

Project/Proposal Start and End Date: 07/2016 – 02/2024

\* Total Award Amount (including Indirect Costs): Butantan pays the cost of the research team directly via its research foundation

\* Person Months (Calendar/Academic/Summer) per budget period.

| Year (YYYY) | Person Months (##.##) |
| --- | --- |
| 1. 2016-2022 | 0.2 |
| 2. 2023  | 0.2 |
| 3. 2024 | 0.2 |

**IN-KIND**

None

**OVERLAP**

None

I, PD/PI or other senior/key personnel, certify that the statements herein are true, complete and accurate to the best of my knowledge, and accept the obligation to comply with Public Health Services terms and conditions if a grant is awarded as a result of this application. I am aware that any false, fictitious, or fraudulent statements or claims may subject me to criminal, civil, or administrative penalties.

\*Signature: ­­­­­­­­­­­­­­­­­­­­­­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date: ­­­­­­­­­­­­­­­­­­­­­­­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_